Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03646123
Title Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seattle Genetics, Inc.
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine

Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab

Age Groups: adult | child | senior
Covered Countries USA | ITA | ESP


No variant requirements are available.